12.06.21
Charlotte, NC-based cbdMD, Inc.—maker of cannabidiol (CBD) brands including topical products in skincare, personal care and body care—has started a preclinical human study with researchers at the University of South Carolina. The study will explore the effects of cbdMD’s proprietary broad spectrum cannabinoid blend on sleep, mood, and pain in healthy subjects to further support the efficacy of the company’s products.
The studies will also be measuring key safety markers in healthy humans to augment the company’s safety dossiers for regulatory submissions. The said it anticipates that the “favorable outcomes” will be the basis for future drug research and applications by its therapeutics division.
“This partnership reaffirms to our consumers that cbdMD is committed to providing products that make a real impact on their daily lives. We expect that this study will not only reaffirm that our products are safe and efficacious to support and maintain a healthy lifestyle but will also serve as the foundation for future work to explore the clinical impact of our broad-spectrum cannabinoid blend on areas that matter most to our customers. We want to educate our customers on the benefits of our products and this study will serve as the foundation for that education. This study is another example of our commitment to safety, quality and efficacy for our customers,” said Sibyl Swift, Ph.D., cbdMD’s VP, scientific and regulatory affairs.
cbdMD’s flagship cbdMD brand currently includes more than 130 SKUs of high-grade, premium CBD products including tinctures, gummies, topicals, bath bombs, bath salts, and other ingestble capsules, sleep aids, and drink mixes along with full spectrum CBD options. The company’s CBD Botanicals brand of beauty and skincare products features15 SKUs, including facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care. It also sells Paw CBD brand of pet products.
Interested in CBD beauty and personal care? Check out the latest issue of CBD Inside & Out.
The studies will also be measuring key safety markers in healthy humans to augment the company’s safety dossiers for regulatory submissions. The said it anticipates that the “favorable outcomes” will be the basis for future drug research and applications by its therapeutics division.
“This partnership reaffirms to our consumers that cbdMD is committed to providing products that make a real impact on their daily lives. We expect that this study will not only reaffirm that our products are safe and efficacious to support and maintain a healthy lifestyle but will also serve as the foundation for future work to explore the clinical impact of our broad-spectrum cannabinoid blend on areas that matter most to our customers. We want to educate our customers on the benefits of our products and this study will serve as the foundation for that education. This study is another example of our commitment to safety, quality and efficacy for our customers,” said Sibyl Swift, Ph.D., cbdMD’s VP, scientific and regulatory affairs.
cbdMD’s flagship cbdMD brand currently includes more than 130 SKUs of high-grade, premium CBD products including tinctures, gummies, topicals, bath bombs, bath salts, and other ingestble capsules, sleep aids, and drink mixes along with full spectrum CBD options. The company’s CBD Botanicals brand of beauty and skincare products features15 SKUs, including facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care. It also sells Paw CBD brand of pet products.
Interested in CBD beauty and personal care? Check out the latest issue of CBD Inside & Out.